Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Zvi Steinberg who wrote (869)	8/2/1999 10:26:00 PM
From: Rick Strange	Read Replies (2) \| Respond to of 1386

How much good news does it take to boost this puppy? Revenues up 158% over prior quarter and net loss down 26% as compared to same quarter last year. LE-T NDA to be filed soon with the FDA. Third leg of HU-211 Phase II trial fully enrolled. Very interesting comment in press release: "We are studying the full range of our development alternatives as we move toward Phase III trial for dexanabinol," said Dr. Aviv. "These alternatives include partnership and joint ventures with investors beyond the limited universe of large pharmaceutical companies." I had taken the Carl Ichan stories with a "grain of salt." Time to rethink the issue. Questions: Does anyone remember a small biotech getting FDA approval on a blockbuster drug prior to structuring a marketing deal with "big pharma?" What kind of a share of revenues did they end up with? How much would PARS have to give up to a joint venture or institutional partner to fund the Phase III trial and approval process? A very complicated set of questions but I'd like to hear your comments.